Literature DB >> 8595153

High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.

J Devlin1, P A Elder, H Gabra, C M Steel, M A Knowles.   

Abstract

We have screened 33 ovarian tumours of various grades and stages for the loss of heterozygosity (LOH) of markers on chromosome 9. LOH was detected in 26 cases (79%). Eleven tumours (33%) showed LOH of all informative markers. The remaining 15 cases had partial deletions. Of these, six (18%) had losses on 9p only, three (9%) had LOH confined to 9q and six (18%) had losses on both chromosome arms, four of which had a retention of hetereozygosity in between. There was no association between tumour grade stage or histopathology and any losses. High-density deletion mapping was carried out in 12 selected cases that had partial deletions of 9p and/or 9q. The deleted region on 9p included the cyclin-dependent kinase inhibitor 2 (CDKN2) locus and one tumour was found to have a homozygous deletion of CDKN2. LOH on 9q extended over a larger region. We found evidence for two regions of deletion on 9q, one at 9q34 and the other encompassing the nevoid basal cell carcinoma (Gorlin) syndrome locus on proximal 9q.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8595153      PMCID: PMC2074458          DOI: 10.1038/bjc.1996.75

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Report and abstracts of the Third International Workshop on Chromosome 9. Cambridge, United Kingdom, 9-11 April, 1994.

Authors:  S Povey; J Armour; P Farndon; J L Haines; M Knowles; F Olopade; A Pilz; J A White; D J Kwiatkowski
Journal:  Ann Hum Genet       Date:  1994-07       Impact factor: 1.670

2.  Homozygous deletion mapping at 9p21 in bladder carcinoma defines a critical region within 2cM of IFNA.

Authors:  J Devlin; A J Keen; M A Knowles
Journal:  Oncogene       Date:  1994-09       Impact factor: 9.867

3.  Short arm deletions in group E and chromosomal "deletion" syndromes.

Authors:  B R Migeon
Journal:  J Pediatr       Date:  1966-09       Impact factor: 4.406

4.  Detailed deletion mapping of chromosome 9q in bladder cancer: evidence for two tumour suppressor loci.

Authors:  T Habuchi; J Devlin; P A Elder; M A Knowles
Journal:  Oncogene       Date:  1995-10-19       Impact factor: 9.867

5.  Fine deletion mapping on the long arm of chromosome 9 in sporadic and familial basal cell carcinomas.

Authors:  S M Shanley; H Dawkins; B J Wainwright; C Wicking; P Heenan; M Eldon; J Searle; G Chenevix-Trench
Journal:  Hum Mol Genet       Date:  1995-01       Impact factor: 6.150

6.  Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumors.

Authors:  G Chenevix-Trench; J Kerr; M Friedlander; T Hurst; B Sanderson; M Coglan; B Ward; J Leary; S K Khoo
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

7.  p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.

Authors:  M P Williamson; P A Elder; M E Shaw; J Devlin; M A Knowles
Journal:  Hum Mol Genet       Date:  1995-09       Impact factor: 6.150

8.  Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers.

Authors:  A G Quinn; S Sikkink; J L Rees
Journal:  Genes Chromosomes Cancer       Date:  1994-12       Impact factor: 5.006

9.  Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.

Authors:  D C Schultz; L Vanderveer; K H Buetow; M P Boente; R F Ozols; T C Hamilton; A K Godwin
Journal:  Cancer Res       Date:  1995-05-15       Impact factor: 12.701

10.  9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene.

Authors:  C Carbonara; L Longa; E Grosso; C Borrone; M G Garrè; M Brisigotti; N Migone
Journal:  Hum Mol Genet       Date:  1994-10       Impact factor: 6.150

View more
  11 in total

1.  Tuberous sclerosis complex 2 loss of heterozygosity in patients with lung disease and cancer.

Authors:  Li Zhang; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Jiro Kato; Mary Haughey; Joseph R Fontana; Vincent C Manganiello; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

2.  Molecular cytogenetic analysis of gene rearrangements in childhood acute lymphoblastic leukemia.

Authors:  Hee Yeon Woo; Dae Won Kim; Hyosoon Park; Ki Woong Seong; Hong Hoe Koo; Sun Hee Kim
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

3.  Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.

Authors:  S Marchini; A M Codegoni; C Bonazzi; S Chiari; M Broggini
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

4.  CDKN2A gene inactivation in epithelial sporadic ovarian cancer.

Authors:  D Niederacher; H Y Yan; H X An; H G Bender; M W Beckmann
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

5.  Prognostic Impact of ABO Blood Group on the Survival in Patients with Ovarian Cancer.

Authors:  Juan Zhou; Li-Chao Yang; Zhen-Yu He; Fang-Yan Li; San-Gang Wu; Jia-Yuan Sun
Journal:  J Cancer       Date:  2015-08-08       Impact factor: 4.207

6.  Effect of blood type on survival of Chinese patients with esophageal squamous cell carcinoma.

Authors:  Jian Qin; San-Gang Wu; Jia-Yuan Sun; Huan-Xin Lin; Zhen-Yu He; Qun Li
Journal:  Onco Targets Ther       Date:  2015-04-23       Impact factor: 4.147

7.  Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.

Authors:  Jihoon Choi; Danai G Topouza; Anastasiya Tarnouskaya; Sean Nesdoly; Madhuri Koti; Qing Ling Duan
Journal:  BMC Cancer       Date:  2020-05-13       Impact factor: 4.430

8.  Histotype-specific copy-number alterations in ovarian cancer.

Authors:  Ruby Yunju Huang; Geng Bo Chen; Noriomi Matsumura; Hung-Cheng Lai; Seiichi Mori; Jingjing Li; Meng Kang Wong; Ikuo Konishi; Jean-Paul Thiery; Liang Goh
Journal:  BMC Med Genomics       Date:  2012-10-18       Impact factor: 3.063

9.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.

Authors:  Louis S Pymar; Fiona M Platt; Jon M Askham; Ewan E Morrison; Margaret A Knowles
Journal:  Hum Mol Genet       Date:  2008-04-07       Impact factor: 6.150

10.  Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation.

Authors:  J Dent; G D Hall; N Wilkinson; T J Perren; I Richmond; A F Markham; H Murphy; S M Bell
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.